Our clinical trials

Cantargia’s clinical program

Nadunolimab (CAN04)

The IL1RAP-binding antibody CAN04 is Cantargia’s lead asset and is investigated in multiple clinical trials in combination with chemotherapy or immunotherapy, summarized in the table below. The clinical program for CAN04 primarily focuses on pancreatic cancer (PDAC), triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).

Overview of Cantargia’s clinical studies for CAN04.

CAN10

In the CAN10 project, an additional IL1RAP-targeting antibody is being developed for treatment of inflammatory and autoimmune diseases. The initial focus will be on two severe diseases: myocarditis and systemic sclerosis. CAN10 recently reached clinical development stage and treatment was started in a phase I clinical trial in September 2023.